'Duke clinical research institute' presentation slideshows

Maximizing Comparative Effectiveness Research The DECIDE CV Consortia

Maximizing Comparative Effectiveness Research The DECIDE CV Consortia. Eric D. Peterson, MD, MPH Professor of Medicine Vice Chair for Quality, Duke DOM Associate Director, Duke Clinical Research Institute (DCRI) David Magid, MD, MPH Director of Research, Colorado Permanente Medical Group

458 views • 35 slides

Coronary Artery Bypass Graft Surgery in Patients with Ischemic Heart Failure

547 views • 30 slides

Impact of Time of Presentation on the Care and Outcomes of Acute Myocardial Infarction

Impact of Time of Presentation on the Care and Outcomes of Acute Myocardial Infarction.

490 views • 29 slides

General Overview

Advanced Practice of Pharmacy Experience: Journal Club Mai Nguyen Mercer University COPHS Doctor of Pharmacy Candidate 2012 Preceptor: Dr. Ali Rahimi October 20, 2011. General Overview. Background.

513 views • 25 slides

Diuretic Optimization Strategies Evaluation in Acute Heart Failure (DOSE)

810 views • 24 slides

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial . Presented on behalf of the ARISTOTLE Investigators and Committees. Sponsored by Bristol-Myers Squibb and Pfizer. Background.

1.97k views • 24 slides

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial . Presented on behalf of the ARISTOTLE Investigators and Committees. Sponsored by Bristol-Myers Squibb and Pfizer. Background.

704 views • 24 slides

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial

Apixaban versus Warfarin in Patients with Atrial Fibrillation Results of the ARISTOTLE Trial . Presented on behalf of the ARISTOTLE Investigators and Committees. Sponsored by Bristol-Myers Squibb and Pfizer. Background.

479 views • 24 slides

Transradial PCI in Octogenarians: Caveats, Tips, and Tricks

Transradial PCI in Octogenarians: Caveats, Tips, and Tricks. Sunil V. Rao MD The Duke Clinical Research Institute The Durham VA Medical Center Duke University Medical Center. Disclosures. Consultant, Honoraria

346 views • 24 slides

Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of INR Control for Stroke Prevention in At

Efficacy and Safety of Apixaban Compared with Warfarin at Different Levels of INR Control for Stroke Prevention in Atrial Fibrillation . Presented by Lars Wallentin, Uppsala Clinical Research Center, Uppsala University, Sweden for the ARISTOTLE investigators. Background.

494 views • 19 slides

Anil Verma, MD, Jalal Ghali, MD, Alessandra Meris, MD, J. Malcolm O. Arnold, MD, Mikhail Bourgoun, MD, Eric Velazquez,

Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) Echocardiographic Study.

589 views • 17 slides

Anil Verma, MD, Jalal Ghali, MD, Alessandra Meris, MD,

Prognostic Implications of Left Ventricular Mass and Geometry Following Myocardial Infarction: the VALsartan In Acute myocardial iNfarcTion (VALIANT) Echocardiographic Study.

362 views • 17 slides

Annual Business Meeting & Class of 2017 Fellows

Annual Business Meeting & Class of 2017 Fellows. May 8, 2017 Arena and Convention Center Liverpool, United Kingdom. Class of 2017 Fellows. Susan Halabi Chair, Fellows Committee. Gerald Beck Ian Ford Ivan S. F. Chan Virginia J. Howard Simon Day Scott Rushing

153 views • 15 slides

Mark Y. Chan Associate Professor Yong-Loo Lin School of Medicine Senior Consultant

Dynamic Risk Stratification in ACS. Mark Y. Chan Associate Professor Yong-Loo Lin School of Medicine Senior Consultant National University Heart Centre, Singapore. Question 1: Does a change in biomarker levels over time confer a change in prognosis in patients with ACS?.

158 views • 15 slides

Purpose

Comparison of bivalirudin versus heparin(s) during percutaneous coronary intervention in patients receiving prasugrel. Martial Hamon 1 , Steven Marso 2 , Sunil Rao 3 , Marco Valgimigli 4 , Freek Verheugt 5 , Anthony Gershlick 6 , Yamei Wang 8 , Gabriel Steg 7 , Efthymios Deliargyris 8

239 views • 13 slides

Outcomes Data

167 views • 12 slides

Cardiovascular Data Analysis Model HL7 Balloting ( September 22 , 2011)

Cardiovascular Data Analysis Model HL7 Balloting ( September 22 , 2011). Salvatore Mungal Duke Bioinformatics Shared Resources (DBSR) Duke Cancer Institute (DCI). Agenda. Background : Stakeholders Harmonization of the data elements HL7 Balloting Converting to the RIM (RIM mapping)

228 views • 11 slides

Patients with HF have increased risk for thrombotic events.

Prescribing Warfarin at Discharge for Heart Failure Patients: Findings from the Get With The Guidelines-Heart Failure Registry . Zubin J. Eapen, Maria Grau-Sepulveda, Gregg C. Fonarow, Paul A. Heidenreich, Eric D. Peterson, Adrian F. Hernandez .

131 views • 1 slides

CBG metaprotein composition shown in Figure 2.

Serum Proteomic Profiles Associated with IL28B Genotype among CHC Patients. Jeanette J. McCarthy 1 , Derek Cyr 1 , Joseph Lucas, 1 J. Will Thompson, 1 Keyur Patel 2 , Alexander Thompson 2 , Hans L. Tillmann, 2 , Paul J. Clark 2 , M. Arthur Moseley 1 and John G. McHutchison 2.

188 views • 1 slides

Vascular Intervention Project (VIP)

Vascular Intervention Project (VIP) Team Co-leads: Kevin L. Thomas, M.D., FACC, FAAC, Duke Division of Cardiovascular Disease/Duke Clinical Research Institute

146 views • 1 slides